RSS
Sitemap
Contact
Search
About HMA
Human Medicines
Veterinary Medicines
You are here:
Home
>
Human Medicines
>
CMDh
>
Pharmacovigilance
>
RMP
CMDh
About CMDh
Statistics
Agendas and Minutes
Press Releases
COVID-19
Nitrosamine impurities
Procedural Guidance
CMDh-Referrals
Product Information
Advice from CMDh
Templates
CMD Working Parties / Working Groups
Paediatric Regulation
Pharmacovigilance
General Information
Referrals
PSUR
RMP
HaRP Assessment Reports
Article 57
Falsified Medicines
Questions & Answers
Contact Points
Recently Published history
MRI Product Index
Pharmacovigilance
Availability of Medicines
Publications and reports
National Contacts
Risk Management Plans
Cover Note to List of safety concerns per approved Risk Management Plan (RMP) of active substances per product
(April 2021) [
Track version
]
Annex 1:
Form for providing list of safety concerns for approved RMPs/updates to list
Annex 2:
HaRP (Harmonisation of RMP Project) - methodology of harmonising RMPs
(April 2021) [
Track version
]
List of safety concerns per approved Risk Management Plan (RMP) of active substances per product
(July 2025)
(If you experience any difficulties to open the documents, please check the local security options in your local system/PC and/or within your browser (see also the browser option "open with")
The update of the CMDh List of safety concerns per approved Risk Management Plan (RMP) of active substances per product is currently delayed.
A new technical, database-driven solution is under development by CMDh.
Flow chart on the assessment and procedure for adoption by CMDh of HaRP Assessment reports prepared by the HaRP Peer Review Group
(February 2021)
